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Background: Cardiovascular risk in psoriasis (PS) appears to be dependent on disease severity. Circulating
endothelial cell (CEC) counts appear to be elevated in numerous conditions associated with endothelial
dysfunction including chronic immune-mediated inﬂammatory disorders. Adipokines could serve as a
missing link between PS and comorbidities
Aim: To evaluate the numbers of CECs and serum visfatin levels in PS patients in comparison to controls
to investigate their possible role in increased cardiovascular disease (CVD) risk.
Methods: Twenty-ﬁve PS patients and 15 healthy individuals were recruited. CECs numbers were
detected in peripheral blood samples through studying CD146 and CD45 expression by ﬂow cytometry.
Serum visfatin levels were detected by enzyme-linked immunosorbent assay.
Results: There was a statistically signiﬁcant increase in CEC numbers and serum visfatin levels in PS
patients compared to controls (p < 0.001) with signiﬁcant positive correlations between serum visfatin
levels and PS severity and numbers of CECs in PS patients. Also, there was a signiﬁcant difference in
numbers of CECs (p  0.001) and serum visfatin levels (p  0.001) between CVD risk positive and CVD
risk negative psoriasis patients.
Conclusion: Both numbers of CECs and serum visfatin levels were increased in PS patients compared with
controls and also increased in CVD risk positive when compared with CVD risk negative PS patients. Both
correlated with disease severity suggesting the possibility of increased CVD risk in PS patients.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Psoriasis (PS) is an immune-mediated inﬂammatory skin disease
characterized by epidermal hyperproliferation, impaired differen-
tiation of keratinocytes, excessive angiogenesis, and immunological
dysfunction.1,2
Circulating endothelial cells (CECs) are thought to be mature
cells that have detached from the intimal mono layer in response to
endothelial injury.2 The study of human endothelial injury isy have no ﬁnancial or non-
atter or materials discussed
logy & Venereology, Tanta
treet, Tanta, El-Garbia, 31111,
rhy).
ical Association. Published by Els
.difﬁcult due to inaccessibility of the endothelium. However, CECs
may serve as a new marker for microvascular injury.3 When these
cells detach from damaged vasculature into the blood, they can be
detected by the expression of CD34 and CD146 and the absence of
CD45 expression.4
CEC counts appear to be elevated in numerous conditions
associated with endothelial dysfunction and injury, including car-
diovascular, hematological, or chronic immune-mediated inﬂam-
matory disorders.5 Several studies indicated increased risk of
cardiovascular disease in patients with PS.6e8 Therefore, assess-
ment of endothelial function might represent a useful prognostic
indicator of increased cardiovascular risk in PS.9
Visfatin (preeB-cell colony enhancing factor) is a 52-kDa protein
secreted primarily by visceral fat. Various cells such as neutrophils,
monocytes, macrophages as well as epithelial and endothelial cells
might be a source of visfatin after induction with inﬂammatory
stimuli.10 It has several proinﬂammatory and immune-modulatingevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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timulatory molecules such as CD80, CD40 and intercellular adhe-
sion molecule-1.11 Visfatin has been proposed as a marker of
endothelial dysfunction and an initial and crucial step in the pro-
gression of the atherosclerotic process,12 and may play a signiﬁcant
role in PS pathophysiology.13 It could provide a link between PS and
cardiovascular morbidity as it was shown to be upregulated in
atherosclerotic plaques in myocardial infarction.14
Materials and Methods
Participants
Twenty-ﬁve patients with plaque-type PS were recruited to the
study. A total of 15 healthy volunteers were enrolled as controls,
matched in age and sex. Exclusion criteria included: known car-
diovascular disease, chronic renal or liver disease, diabetesmellitus,
and skin disease other than psoriasis, malignancies or any signiﬁ-
cant abnormalities in blood count. The psoriatic patients did not
receive any topical or systemic therapy at least 3 months prior to
the initiation of the study. Demographic data as well as information
regarding onset and duration of psoriasis were documented
(Table 1). Psoriasis severity was assessed with Psoriasis Area and
Severity Index (PASI) score.15 The study was approved by the local
research ethical Committee (approval code 1455/11/12).
Cardiovascular disease risk screening
All patients were screened for arterial hypertension (systolic blood
pressure 140 mmHg or diastolic blood pressure 90 mmHg) and
hypercholesterolemia (elevated level of total and/or low-density
lipoprotein cholesterol; Table 1).
Detection of CECs
The evaluation of CECs numbers was performed with ﬂow cytom-
etry, using FACSCalibur cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA). Peripheral blood samples were incubated with
selected antibodies (anti-human CD146 Phycoeritrin Conjugated
Mouse IgG1; R&D System, Minneapolis, MN, USA; anti-human
CD45ePerCP; Becton Dickinson) at the concentrations suggested
by the manufacturers. After incubation, cells were treated with
Lysing Solution (Becton Dickinson) to eliminate erythrocytes.
Fluorescent CytoCount beads (Dako Cytomation) were added for
precise cell number evaluation. At least 10,000 events were
collected. CECs were evaluated using gate for mononuclear cells
and data were expressed as cells/mL of blood (Figure 1).16,17 TheTable 1 Basic and laboratory data of the studied psoriasis patients and controls.
Characteristic Psoriatic patients
Age (y), mean ± SD 46.16 ± 14.83
Female (%) 44
Body mass index (kg/m2) 28.43 ± 6.27
CVD risk Arterial hypertension 3 (12%)
Hypercholesterolemia 5 (20%)
PASI, range 7.0e35.0
Mean ± SD 21.32 ± 8.49
Mean duration of psoriasis (y) 6.88 ± 6.87
Onset of psoriasis <40 y (%) 48
Positive family history (%) 36
CECs/mL, range 1274.0e3916.0
Mean ± SD 2230.0 ± 784.93
Serum visfatin levels (ng/mL), mean ± SD 78.6 ± 48.1
p < 0.05 is considered statistically signiﬁcant.
CECs ¼ circulating endothelial cells; CVD ¼ cardiovascular disease; PASI ¼ Psoriasis Aremean, median, maximal, minimal, and standard deviation of values
was calculated. The signiﬁcance of differences between categorical
variables were determined by Pearson's Chi-square test or Chi-
square with Fisher's exact test. The relationships between two
quantitative variables were assessed using Pearson's coefﬁcient.
Statistical signiﬁcance was set at p < 0.05.
Detection of serum visfatin level
Blood samples were obtained the morning after a 12-hour over-
night fast. Samples were immediately centrifuged at 750 g for 15
minutes. Serum samples were stored at70C for subsequent assay
according to the manufacturer's instructions (human/mouse/rat
visfatin enzyme immunoassay kit; RayBiotech, Norcross,GA, USA).18
Serum visfatin levels were detected in all samples using an
enzyme-linked immunosorbent assay.
Results
The CEC counts were signiﬁcantly increased in psoriatic patients
compared to controls (p < 0.001; Table 1, Figure 1). Moreover, CEC
counts were signiﬁcantly, positively correlated with disease
severity, assessed with PASI (r ¼ 0.869, p < 0.001; Figure 2). There
was signiﬁcant increase in the numbers of CECs in severe PS
compared to the mild and moderate PS groups (p < 0.001). How-
ever, there was an insigniﬁcant increase in CEC counts in moderate
PS compared to mild PS (p ¼ 0.076). There was no statistically
signiﬁcant difference in CECs numbers betweenmen andwomen in
psoriatic patients and also in the controls (p¼ 0.192; Table 2). There
was no signiﬁcant relation between the number of CECs and pa-
tients' age or disease duration. Serum visfatin levels were signiﬁ-
cantly increased in psoriatic patients when compared with controls
(p < 0.001; Table 1). There were signiﬁcant positive correlations
between serum visfatin levels and disease severity, assessed with
PASI (r ¼ 0.869, p < 0.001; Figure 3) as well as the numbers of CECs
(r ¼ 0.76, p ¼ 0.001; Figure 4). There was signiﬁcant difference in
numbers of CECs (p  0.001) and serum visfatin levels (p  0.001)
between cardiovascular disease (CVD) risk-positive and CVD risk-
negative PS patients (Table 3).
Discussion
Impairment of endothelial function may constitute the link be-
tween chronic systemic inﬂammatory process and increased CVD
risk in psoriatic patients that has been already proposed in the
concept of the psoriatic march.7 There is growing clinical evidence
supporting a role for visfatin as a biomarker or even a predictor of(n ¼ 25) Controls (n ¼ 15) Statistics p
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432.0e1210.0 t ¼ 8.2 0.001
865.47 ± 210.57
9.7 ± 4.9 t ¼ 7.1 0.001
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Figure 1 Increased number of circulating endothelial cells evaluated in peripheral blood by using ﬂow cytometry as CD146þ⁄CD45e cells in (A) psoriatic patients compared with (B)
controls.
Figure 2 Signiﬁcant positive correlation between numbers of circulating endothelial cells (CECs) and Psoriasis Area and Severity Index (PASI) Score.
Table 2 Relationship between psoriasis severity and age, sex, disease duration, circulating endothelial cells (CECs) counts, and serum visfatin levels in the studied psoriasis
patients.
Characteristic PASI Score
n ¼ 25
Statistics p
Mild
5 (20%)
Moderate
11 (44%)
Severe
9 (36%)
Age (y), mean ± SD 32.8 ± 6.1 43.2 ± 15.7 57.2 ± 8.5 F ¼ 7.2 0.004
Female (%) 60 45.5 33.3 FET 0.689
Mean duration of psoriasis (y) 4 ± 3.7 7.50 ± 6.1 10.8 ± 6.8 F ¼ 2.1 0.14
PASI 9 ± 1.6 17.7 ± 5.9 31.9 ± 3.3 F ¼ 46.3 0.0001
CECs/mL Male 1422.50 ± 30.41 2026.17 ± 344.74 3080.0 ± 580.51
Female 1335.67 ± 63.58 2350.0 ± 1909.60 2905.0 ± 878.89
p 0.181 0.635 0.726
Total 1370.40 ± 69.19 1973.18 ± 376.43 3021.67 ± 641.39 F ¼ 23.4 0.001
Serum visfatin levels 28.6 ± 9.3 59.5 ± 15.3 129.7 ± 40.1 F ¼ 1.4 0.5
p < 0.05 is considered statistically signiﬁcant.
FET ¼ Fisher's exact test; PASI ¼ Psoriasis Area and Severity Index; SD ¼ standard deviation.
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diseases.19
To our knowledge, the present study is the ﬁrst to investigate
CECs and serum visfatin level simultaneously in relation to car-
diovascular disease in psoriasis patients. There were signiﬁcantdifferences in numbers of CECs and serum visfatin levels between
CVD risk positive and CVD risk negative psoriasis patients.
Endothelial cells have a pivotal role in the initiation and
development of defensive and damaging inﬂammatory responses,
serving as the source of multiple factors and mediators such as
Figure 3 Signiﬁcant positive correlation between numbers of circulating endothelial cells (CECs) and serum visfatin level.
Figure 4 Signiﬁcant positive correlation between serum visfatin levels and Psoriasis Area and Severity Index (PASI) Score.
Table 3 Relation between cardiovascular disease (CVD) and circulating endothelial cells (CECs) numbers and serum visfatin levels in psoriasis patients.
Variable CVD risk positive psoriasis patients (n ¼ 8) CVD risk negative psoriasis patients (n ¼ 32) Statistic p
Mean SD Mean SD
No. of CEC 3118.5 612.4 1368.3 585.7 t ¼ 7.5 0.001
Serum visfatin level 136.5 37.1 31.8 25.9 t ¼ 9.3 0.001
p < 0.05 is considered statistically signiﬁcant.
SD ¼ standard deviation.
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inﬂammatory mediators.20 The rate of vascular proliferation in
active psoriasis is similar to that in other angiogenic pathologies;
hypothetically, increased level of CECs may have a certain role in
pathogenesis of psoriasis.5
It has been described that visfatin can promote endothelial cell
proliferation, migration, and capillary tube formation.21,22 It has
proangiogenic effects through thromboxane A2 released by endo-
thelial cells.23 Visfatin can directly promote vascular inﬂammation
by activating endothelial cells and vascular smoothmuscle cells and
also through its immunomodulatory properties on immune cells.24
Several reports have suggested that visfatin can additionally pro-
mote endothelial activation through activation of nuclear factor-
kB25e27 and promotion of cell adhesion molecules expression, suchas ICAM-1, VCAM-1, or E-selectin,25,26 as key molecules implicated
in leukocyte recruitment and early pro-atherosclerotic events.28
A single report by Lovren et al29 proposed human endothelial
cells as an additional source for visfatin within the vascular wall.
Similarly, visfatin mRNA expression was reported in endothelial
cells.30
In the present study the mean number of CECs was signiﬁcantly
elevated in PS patients when compared with controls. This ﬁnding
matched the results of Arenberger et al31 and Sochorova et al32; in
both studies CECs were counted in peripheral blood smears with
microscopic methods. In addition, Yiu et al6 and Boehncke et al7
reported endothelial dysfunction in PS by demonstrating
increased levels of soluble markers of endothelial dysfunction,
(such as von Willebrand factor or sE-selectin) or impaired ﬂow-
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dysfunction and increased risk of CVD in psoriatic patients when
compared with controls.
The current study showed a signiﬁcant increase in the numbers
of CECs in severe PS when compared with each of the mild and
moderate PS groups. Moreover, a positive correlation was observed
between the numbers of CECs and PS severity according to PASI
score. This result was in agreement with those of Yiu et al,6
Batycka-Baran et al,33 and Davidovici et al.34 This may indicate
that the increased risk of CVD in PS is correlated with PS severity.
By contrast, there were no signiﬁcant correlations between the
numbers of CECs and patient's age or disease duration. Also, no
signiﬁcant difference between CEC counts in men and women was
observed. These results were in agreement with Sochorova et al.32
The current study revealed that serum visfatin levels were
signiﬁcantly elevated in PS patients when compared with controls.
This ﬁnding matched the results of Ismail and Mohamed.13 Serum
visfatin levels showed signiﬁcant positive correlation with PASI
score of the studied group. This ﬁnding was in agreement with that
of Gerdes et al10, who proposed visfatin as a marker of PS severity
and chronicity.
The role of visfatin in PS might include modulation of the in-
ﬂammatory or immune response as it induces chemotaxis and in-
creases the production of interleukins-1 and -6, tumor necrosis
factor-a, and costimulatory molecules by CD14þ monocytes. This
enhances their ability to induce proliferative responses.35 Another
explanation is that visfatin level might be upregulated during
inﬂammation and in response to proinﬂammatory cytokines.36
Raised visfatin values could be attributed to its production by
cells involved in PS.11
In PS, in vivo data showed an increase of the gene expression
proﬁle of visfatin,37 and in vitro data showed a visfatin enhanced
tumor necrosis factor-a-induced CXC chemokine ligands 8 and 10
as well as CC chemokine ligand 20 secretions andmRNA expression
in human keratinocytes. Thus, visfatin may be involved in the
inﬁltration of Type 1 or Type 17 helper T cells or neutrophils to the
skin, and therefore participates in the pathophysiology of PS.38
Also, similar results were observed in another study analyzing
gene expression of visfatin from psoriatic and control skin
samples.39
In the present study, serum visfatin levels showed signiﬁcant
positive correlation with CECs number in the studied group. Vis-
fatin may rather be a biomarker of inﬂammation and endothelial
damage, and also a direct regulator of the cardiovascular system
that modulates cell proliferation and survival, extracellular matrix,
vascular reactivity, and inﬂammation. Conversely, the administra-
tion of visfatin has shown beneﬁcial effects in different ischemic
conditions. Further research is required to evaluate the real value of
visfatin as a pharmacological target.40
Visfatin could serve as a missing link in the causal relationship
between PS and comorbidities and may provide a biomarker for
disease severity, risk of comorbidities and treatment success.18References
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